Cadrenal Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CVKD | PCSA | TRAW | NXTC | HBP.TO | EDSA | |
|---|---|---|---|---|---|---|
| Market cap | 3.78M | 5.41M | 4.13M | 26.78M | 70.27M | 29.32M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.3 | -0.5 | -0.1 | -1.0 | -8.4 | — |
| Price/book | 0.8 | -17.0 | 2.4 | 2.0 | 4.8 | 52.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −91.14% | −75.51% | −86.18% | −38.63% | −54.68% | +27.65% |
| Today | −6.19% | −0.26% | −11.06% | −1.02% | 0.00% | −4.82% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CVKD news ›Cadrenal Therapeutics evaluating strategic options
Cadrenal Therapeutics Inc. announced Oct. 7 it initiated a strategic review process to evaluate opportunities, which could include a sale of its drugs in development. The Ponte Vedra Beach-based pharmaceutical company was formed in January…
CalciMedica grants Zaytsev 20,000 stock options
CalciMedica, Inc. (CALC) is a La Jolla-based clinical-stage biopharma developing CRAC channel inhibitors like Auxora for severe inflammatory diseases. CalciMedica grants Zaytsev 20,000 stock options The director's option award vests in…
Cadrenal Therapeutics grants director 75,000 options
Cadrenal Therapeutics (CVKD) is a Nasdaq-listed biopharmaceutical company developing clinical-stage anticoagulant drugs for high-risk and rare patient populations. - [Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity Cadrenal…
Cadrenal Therapeutics starts strategic review
Cadrenal says it recently aligned with the FDA on a Phase 3 development pathway for CAD-1005. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 7, 2026 (Exact…
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
October 07, 2026 07:00 ET | Source: Cadrenal Therapeutics Inc. Cadrenal Therapeutics Inc. Cadrenal has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor in connection with the process. There can be no…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net5
- globenewswire.com1
- jaxdailyrecord.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.